Introduction
============

Bisphenol A \[BPA; 2,2-bis (4-hydroxyphenyl)\], an environmental contaminant, is an increasingly produced worldwide chemical ([@b1-etm-0-0-8193]). BPA is used in the manufacture of polycarbonate plastics, epoxy resins and hard plastic bottles, which are commonly consumed products ([@b2-etm-0-0-8193]). Epoxy resins are used in food-contact surface lacquer coatings for cans, automobile parts and as a coating for PVC pipes ([@b3-etm-0-0-8193]). The increased use of these products has led to a BPA content of \>90% in various human biological fluids, including human breast milk, amniotic fluid and neonatal blood ([@b4-etm-0-0-8193]). The primary route of BPA exposure is via ingestion ([@b1-etm-0-0-8193]), but transdermal absorption and inhalation are probable secondary exposure routes, particularly in individuals who work in companies that produce BPA-based products ([@b3-etm-0-0-8193],[@b5-etm-0-0-8193]). BPA is an endocrine-disrupting substance with estrogenic and thyroid hormone-like effects ([@b6-etm-0-0-8193]). Several studies have reported that BPA exposure promotes hepatotoxicity and induces oxidative damage via different mechanisms ([@b7-etm-0-0-8193],[@b8-etm-0-0-8193]). Other studies have determined an association between BPA exposure and an increased risk of reproductive dysfunction, cardiovascular disease, obesity, type II diabetes and thyroid dysfunction ([@b6-etm-0-0-8193],[@b9-etm-0-0-8193]). Sesame (*Sesamum indicum L*.) is a crop that is produced worldwide. It has been cultivated in Asia and Africa for its high content of edible oil and protein ([@b10-etm-0-0-8193]) and has been used as a traditional food source in the countries of East Asia ([@b11-etm-0-0-8193]). Sesame oil is considered to be a superior vegetable oil, as it has a high nutritional value ([@b12-etm-0-0-8193]) that is therapeutically effective within 3--12 h after oral administration ([@b13-etm-0-0-8193]). Sesame oil decreases blood pressure, lipid profiles and lipid peroxidation, and increases enzymatic and nonenzymatic antioxidants ([@b14-etm-0-0-8193]). The potent antioxidant activity of sesame oil is due to its high content of polyunsaturated fatty acids and lignans ([@b15-etm-0-0-8193]). Sesame lignans include sesamin, sesamolin, sesamol, sesaminol, sesamolinol, pinoresinol, matairesinol, lariciresinol and episesamin, which all exhibit a broad spectrum of biological properties ([@b16-etm-0-0-8193]). Sesame lignans individually or in combination, exhibit different biological activities. Sesamin has been revealed to serve an important role in lipid and glucose metabolism, hypertension, anti-inflammation and free radical scavenge ([@b17-etm-0-0-8193]). Sesamolin promotes apoptosis, suppresses neuronal reactive oxygen species (ROS) generation and attenuates mutagenesis induced by H~2~O~2~ ([@b18-etm-0-0-8193],[@b19-etm-0-0-8193]). Furthermore, sesaminol inhibits DNA oxidative damage, decreases low-density lipoprotein (LDL) oxidation induced by copper and inhibits membrane lipid peroxidation ([@b20-etm-0-0-8193],[@b21-etm-0-0-8193]). Yashaswini *et al* ([@b22-etm-0-0-8193]) reported that the oral administration of sesamol and sesamin modulates inflammatory and oxidative damage markers in lipopolysaccharide (LPS)-injected rats. However, to the best of our knowledge, there are no *in vivo* studies assessing the protective effect of sesame lignans against BPA-induced hyperlipidemia and oxidative damage. Accordingly, the aim of the current study was to investigate the modulative effects of sesame lignans against BPA-induced hepatic and cardiac toxicity in rats. This was achieved by performing liver and heart function tests, determining lipid profiles and assessing the levels of certain oxidants and antioxidants. Biochemical parameters were also confirmed via histopathological examinations of liver and heart tissue. In addition, the dorsal aorta was quantitatively analyzed.

Materials and methods
=====================

### Chemicals

BPA, glutathione reductase (GR), glutathione (GSH), pyrogallol, NADPH, 2-thiobarbituric acid, 1,1,3,3-tetraethoxypropane, 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) and bovine serum albumin were purchased from Sigma-Aldrich (Merck KGaA). All other general chemicals and kits were of analytical grade.

### Extraction and purification of sesame lignans

Sesame lignans were extracted and purified as described by Reshma *et al* ([@b23-etm-0-0-8193]). Sesame oil (100 g) was mixed with methanol (1:1 w/v) in an extraction vessel. The mixture was then stirred for 10 min at 70°C and transferred into a separating funnel. Following 15 min of settling time, the methanolic extract was separated from the residual oil, which was subsequently stripped of solvent and subjected to 9 additional sequential extractions with fresh batches of methanol performed exactly as described above. The 10 methanolic extracts were pooled and concentrated via evaporation at 40°C using a rotary evaporator (Model 4622; BUCHI Rotavapor™ R-100; Thermo Fisher Scientific, Inc.). These extracts were then dispersed in petroleum ether at a ratio of 1:0.5 (w/v). The mixture was left to stand for 24--48 h at 4°C to facilitate the lignan crystallization. Lignan crystals were separated from the mixture via filtration, washed with cold petroleum ether, dried in a vacuum oven at a temperature of 40°C for 1 h and weighed.

### Experimental design

A total of 40 adult male Wister albino rats (weight, 150--160 g) were obtained from the animal house of Faculty of Medicine, Alexandria University, Egypt. The design and experimental techniques of the current study were approved by the Institutional Animal Care and Use Committee (IACUC) of Alexandria University in accordance with the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimise the suffering of rats during the experimental period. Rats were housed in stainless steel cages and provided with a basal diet and tap water *ad libitum*. Animals were maintained under 25°C and a 12 h light/dark cycle with relative humidity 50--60% during the experimental period. Rats were equally and randomly divided into the following four groups (each, n=10): A control group (C-group), a BPA-treated group (B-group) that received 30 mg/kg ([@b24-etm-0-0-8193]), a sesame lignans-treated group (S-group) that were treated with sesame lignans (20 mg/kg) ([@b25-etm-0-0-8193]) and a BPA plus sesame lignans-treated group (BS-group) that received BPA (30 mg/kg) and sesame lignans (20 mg/kg). Rats were orally administered their respective doses daily for 6 weeks.

### Sampling and tissue preparation

At the end of experimental period, rats were starved for 12 h and then deeply euthanized via an intraperitoneal injection of 100 mg/kg ketamine and 20 mg/kg xylazine. The 12 h fasting period prior to sampling did not cause remarkable loss of body weight or any observed adverse effects on rats. After euthanasia, 4 ml of blood was obtained through cardiac puncture using a sterile syringe. Death was subsequently confirmed by the inhalation of CO~2~ from a pressurized tank at a flow rate of 25% per min followed by cervical dislocation. Serum was obtained by centrifugation of clotted blood at 1,000 × g at 25°C for 10 min and kept at −20°C for lipid profiling and liver and heart function tests. Liver, heart and dorsal aorta were immediately isolated and washed with cold saline solution. Pieces of tissue were then fixed for 12 h with 10% formalin at 25°C for histological examination. Liver tissue (0.25 g) was subsequently homogenized individually in 5 ml of 5% trichloroacetic acid, containing 0.003 M EDTA. The homogenate was centrifuged at 500 × g for 15 min at 4°C and the supernatants were stored at −20°C for reduced GSH determination. Additionally, 0.5 g liver tissue was isolated, washed and homogenized in PBS (0.1 M; pH 7.4). The homogenate was centrifuged at 25,000 × g for 10 min at 4°C (Hitachi Ltd.; model, EBA 12R). Supernatants were stored in aliquots of 1ml at −20°C for subsequent biochemical analysis.

### Extraction of hepatic total lipids

Total liver lipid content was measured via gravimetric determination according to a method previously described by Folch *et al* ([@b26-etm-0-0-8193]). Half gram of liver tissue was homogenized in 5 ml of chloroform-methanol mixture (2:1, v/v) using a Polytron homogenizer (model, TR-10; Tekmar). The solvent obtained from the extract was evaporated and the extracted lipids were reconstituted in 0.2 ml petroleum ether and used for the determination of hepatic triglycerides and total cholesterol concentrations.

### Biochemical analysis

Serum aspartate aminotransferase (AST) ([@b27-etm-0-0-8193]), serum alanine aminotransferase (ALT) ([@b27-etm-0-0-8193]) and serum total bilirubin ([@b28-etm-0-0-8193]) were assayed according to their respective previously described methods using commercially available diagnostic kits (Biosystems S.A.). Liver lipid peroxidation end product (malondialdehyde; MDA) was measured by 2-thiobarbituric acid and expressed as nmol MDA/g tissue ([@b29-etm-0-0-8193]). The concentration of MDA in each sample was obtained from a standard curve prepared from a serial dilution of 1,1,3,3-tetraethoxypropane. Reduced GSH was determined in liver homogenate by enzymatic method using NADPH as a reducing agent and dependent on oxidation of GSH by DTNB, as previously described ([@b30-etm-0-0-8193]). GR activity was assayed in the liver tissues as previously described ([@b31-etm-0-0-8193]). Activity of glutathione peroxidase (GPx) was assessed using cumene hydroperoxide as a substrate ([@b32-etm-0-0-8193]). Assay of superoxide dismutase (SOD) based on the ability of SOD to inhibit pyrogallol self-oxidation in alkaline conditions ([@b33-etm-0-0-8193]). Creatine kinase MB (CK-MB) activity was determined as previously described ([@b34-etm-0-0-8193]). Lactate dehydrogenase (LDH) catalyzes the reduction of pyruvate by NADH to form lactate and NAD^+^. This catalytic activity was assayed spectrophotometrically at 340 nm ([@b35-etm-0-0-8193]). All biochemical assays were repeated at least three times. The levels of triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL-C) were determined using commercially available diagnostic kits (Biosystems S.A.). Very low-density lipoprotein cholesterol (VLDL-C) was calculated from the values of TG, TC and HDL-C using Friedwald and Fredrickson\'s formula ([@b36-etm-0-0-8193]).

### Histopathological examination

For histological examination, pieces of liver, heart and aorta were fixed in 10% neutral formalin for 12 h at 25°C. The tissue pieces were dehydrated using ascending concentrations of ethyl alcohol and then embedded in paraffin for 2 h to form blocks. The blocks were trimmed and cut into 6-µm-thick sections. The sections were de-waxed, hydrated and stained with hematoxylin and eosin, as previously described ([@b37-etm-0-0-8193]). Stained sections of liver and heart tissue were examined under a light microscope to assess the histological changes. Quantitative analysis of aorta sections was performed using analysis FIVE digital imaging software (Olympus Corporation) and ImageJ (version 1.46r; National Institutes of Health)

### Statistical analysis

Statistical analysis was performed using SPSS software (Version 16.0; SPSS, Inc.). Data were presented as the mean ± standard error. There were 10 rats in each group and each measurement was repeated three times. Comparisons among group mean differences were assessed via one-way ANOVA. Means were then statistically compared using the Least Significant Difference test (LSD). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Effect of BPA-treatment

As presented in [Table I](#tI-etm-0-0-8193){ref-type="table"}, BPA-treatment caused a significant increase in the activity of serum ALT, AST and total bilirubin compared with the control group. Oral ingestion of BPA (B-group) significantly increased serum levels of TG, TC, LDL-C and VLDL-C compared with the control group (P\<0.05). However, HDL-C levels were significantly decreased (P\<0.05; [Table II](#tII-etm-0-0-8193){ref-type="table"}). The accumulation of lipids in hepatocytes was observed in the BPA-treated group via the significant elevation of TG and TC in liver tissue compared with the control group (P\<0.05; [Fig. 1](#f1-etm-0-0-8193){ref-type="fig"}). Furthermore, BPA treatment caused a significant (P\<0.05) reduction in hepatic GPx, GR and SOD activity, and a decrease in GSH compared with the control group. BPA-treatment also resulted in a significant (P\<0.05) increase in hepatic malondialdehyde (MDA) levels compared with the control group ([Table III](#tIII-etm-0-0-8193){ref-type="table"}). In addition, BPA significantly (P\<0.05) increased the activities of serum CK-MB and LDH compared with the control group ([Figs. 2](#f2-etm-0-0-8193){ref-type="fig"} and [3](#f3-etm-0-0-8193){ref-type="fig"}).

The histological analyses performed in the current study confirmed the deteriorating effect of BPA on both the liver and heart tissues. The control group exhibited normal hepatocyte architecture, central vein, blood sinusoids and hepatocytes ([Fig. 4](#f4-etm-0-0-8193){ref-type="fig"}). BPA treatment caused hemorrhage in the central vein, loss of the normal hepatocyte architecture, degenerated and vacuolized hepatocytes with pyknotic nuclei, dilation of the hepatic sinusoids and lymphocyte aggregation ([Fig. 4Ba and Bb](#f4-etm-0-0-8193){ref-type="fig"}). Histological examinations of heart tissues of the control group revealed normal architecture of the myocardial fibers and branching muscle fibers with centrally located oval nuclei ([Fig. 5A](#f5-etm-0-0-8193){ref-type="fig"}). The examination of the B-group revealed the loss of the normal muscle fiber architecture, loss of cross striations and fragmentation of sarcoplasm, cardiac muscle cell cytoplasmic vacuolization, connective tissue edema, degenerative changes in myocardial fibers with congested blood vessels and the thickening of coronary branches ([Fig. 5Ba and Bb](#f5-etm-0-0-8193){ref-type="fig"}). Examination of the dorsal aorta of the control group revealed a normal tunica intima with a single irregular layer of endothelial cells, tunica media with elastic fibers and a normal tunica adventitia ([Fig. 6A](#f6-etm-0-0-8193){ref-type="fig"}). BPA-treated rats demonstrated sclerotic changes in its walls, atrophy of elastic fibers, loss of tunica intimal endothelial cells, disorganized tunica media and adventitia, and vacuolation of the tunica media and adventitia compared with normal layers of the dorsal aorta of the control group ([Fig. 6Ba and Bb](#f6-etm-0-0-8193){ref-type="fig"}). Furthermore, quantitative analysis of the aortic atherosclerotic composition of the B-group revealed a significant (P\<0.05) increase in mean wall thickness compared with that of the control group ([Table IV](#tIV-etm-0-0-8193){ref-type="table"}).

### Sesame lignans attenuates liver function tests

S-group treatment was revealed to improve rat liver function as indicated by the significant (P\<0.05) reduction in the activities of serum AST, ALT and total bilirubin level compared with the B-group. Furthermore, BS-group treatment significantly (P\<0.05) decreased the aforementioned serum parameters compared with the B-group, returning them to levels similar to that of the control ([Table I](#tI-etm-0-0-8193){ref-type="table"}).

### Sesame lignans improves lipid profiles

As presented in [Table II](#tII-etm-0-0-8193){ref-type="table"}, it was revealed that S-group treatment significantly (P\<0.05) reduced the levels of serum TG, TC, LDL-C and VLDL-C, and significantly (P\<0.05) elevated HDL-C compared with the C- and B-group. The co-administration of sesame lignans and BPA (BS-group) improved levels of the aforementioned lipid profile parameters compared with the B-group. Furthermore, S-group treatment significantly (P\<0.05) reduced hepatic TG and TC levels compared with the control group. The results of [Fig. 1](#f1-etm-0-0-8193){ref-type="fig"} also demonstrated a significant (P\<0.05) reduction in hepatic TG and TC contents in the BS-group compared with the B-group.

### Sesame lignans ameliorates hepatic oxidative status

As presented in [Table III](#tIII-etm-0-0-8193){ref-type="table"}, the results revealed significant (P\<0.05) increases in the activities of hepatic GR, GPx and SOD, and increased levels of GSH in the S-group compared with the control group. Additionally, significant (P\<0.05) increases in the aforementioned antioxidant parameters were observed in the BS-group compared with the B-group. However, MDA levels were significantly (P\<0.05) reduced in the S- and BS-groups compared with the control group and B-group.

### Sesame lignans attenuates cardiac function tests

As presented in [Figs. 2](#f2-etm-0-0-8193){ref-type="fig"} and [3](#f3-etm-0-0-8193){ref-type="fig"}, a non-significant (P\>0.05) change in the serum activity of CK-MB (a cardiac-specific enzyme) was observed in the S-group compared with the control group. However, a significant (P\<0.05) reduction was demonstrated in the serum activity of CK-MB in the BS-group compared with the B-group. In addition, S-group treatment decreased the serum LDH levels to less than that of the control. Furthermore, the activity of serum LDH was significantly (P\<0.05) decreased in the BS-group compared with the B-group.

### Sesame lignans improves hepatic and cardiac histological changes

Photomicrographs of control and sesame lignans-treated liver tissue revealed normal cellular architecture with distinct hepatic cells, sinusoidal spaces and central veins ([Fig. 4A, Ca and Cb](#f4-etm-0-0-8193){ref-type="fig"}). Furthermore, liver sections of rats treated with sesame lignans in combination with BPA revealed that most of the histological alterations induced by BPA were markedly reduced. The histological changes observed after BPA-treatment were also attenuated from severe to moderate after treatment with sesame lignans ([Fig. 4D](#f4-etm-0-0-8193){ref-type="fig"}). Heart sections of the control and sesame lignans-treated groups also demonstrated normal myofibrillar architecture with striations, a branched appearance and continuity with adjacent myofibrils ([Fig. 5A and C](#f5-etm-0-0-8193){ref-type="fig"}). Consistent with this result, sesame lignans treatment in the BS-group markedly reduced heart tissue histopathological alterations following BPA exposure ([Fig. 5D](#f5-etm-0-0-8193){ref-type="fig"}). Histopathological examination of the dorsal aorta in the control and sesame lignans-treated groups revealed a smooth and continuous intimal surface without lumen irregularities ([Fig. 6A and C](#f6-etm-0-0-8193){ref-type="fig"}). Examination of the BS-group dorsal aortas demonstrated a marked reduction in the histological alterations induced by BPA ([Fig. 6D](#f6-etm-0-0-8193){ref-type="fig"}). The quantitative analysis of S- and BS-group aortic compositions revealed a significant (P\<0.05) reduction in the mean wall thickness of the dorsal aorta compared with the B-group ([Table IV](#tIV-etm-0-0-8193){ref-type="table"}).

Discussion
==========

Previous studies have focused on the impact of BPA on human health and have determined that the toxic effects of BPA may be due to enhanced oxidative stress ([@b7-etm-0-0-8193],[@b8-etm-0-0-8193]). The present study revealed that BPA induced hepatic oxidative stress, steatosis and affects the secretory function and integrity of the liver. Increased levels of hepatic MDA, the decreased activities of GPx, GR and SOD, and the decreased levels of GSH indicated that there were increased levels of oxidative stress in liver cells. These results are consistent with that of Maćczak *et al* ([@b38-etm-0-0-8193]) who reported that BPA treatment induces oxidative damage. Another previous study demonstrated that BPA increased lipid peroxidation and decreased the activity of antioxidant defense enzymes produced in rat livers ([@b39-etm-0-0-8193]). The BPA-mediated reduction of GSH levels may be due to its conjugation with BPA-toxic metabolites and its oxidation to oxidized glutathione ([@b40-etm-0-0-8193]). Furthermore, certain lipid peroxidation end products \[including malondialdehyde (MDA) and 4-hydroxynonenal\] are able to alter the activity of mitochondrial enzymes and deplete the glutathione pool ([@b41-etm-0-0-8193]). Decreased GSH levels may therefore lead to decreased GPx activities ([@b42-etm-0-0-8193]). Decreased GPx activity is associated with an increased level of the hepatic H~2~O~2,~ as well as the direct inhibition of SOD activity ([@b43-etm-0-0-8193]). It has been reported that BPA reacts with oxygen radicals, decomposing them to various reactive metabolites that have potent oxidant activity ([@b44-etm-0-0-8193]). These metabolites increase ROS production, inhibit the activity of antioxidative enzymes and increase H~2~O~2~ and thiobarbituric acid reactive substance levels ([@b44-etm-0-0-8193]). The BPA-mediated increase of ROS may enhance the cleavage of peptide chains and the cross-linking of amino acids in enzymes, leading to the change or loss of enzyme activity ([@b45-etm-0-0-8193]). Therefore, the mechanism of BPA-induced oxidative damage may be primarily caused by the inhibition of the antioxidant enzyme system, increasing ROS content.

In the present study, BPA induced a dyslipidemic state and enhanced the accumulation of triglycerides (steatosis) and cholesterol in rat liver tissue. These results are consistent with those of Lin *et al* ([@b46-etm-0-0-8193]), who demonstrated that BPA induced the intracellular accumulation of fat droplets in a dose-dependent manner. Furthermore, it has been reported that BPA exposure results in hypertriglyceridemia, hypercholesterolemia, changes in the composition of fatty acids and the upregulation of genes associated with *de novo* lipogenesis and cholesterol synthesis in rat livers ([@b47-etm-0-0-8193]). BPA-induced hepatic lipid accumulation may arise from the increased expression of the transcription factor, sterol regulatory element binding protein-1, which increases the quantity and activity of the enzymes that catalyze lipogenesis, triggering hepatic lipid accumulation ([@b46-etm-0-0-8193]). The BPA-induced increase of VLDL-C may be due to the increased synthesis and excretion of VLDL-C from liver tissue as a result of the increased hepatic mRNA expression of apolipoprotein B ([@b48-etm-0-0-8193]). The increased hepatic output of VLDL-C may therefore be a consequence of increased hepatic TG.

BPA-induced oxidative stress and lipid peroxidation has been demonstrated to increase hepatic damage and disrupt the integrity of cellular membranes, leading to leakage of cytoplasmic liver enzymes ([@b49-etm-0-0-8193]). The present study revealed that BPA caused significant increases in the activities of ALT and AST, and in the level of total bilirubin. These results are congruent with the results of a previous study by Korkmaz *et al* ([@b50-etm-0-0-8193]). The results of the aforementioned study revealed that BPA-treatment elevated the activities of ALT, AST and LDH, and caused marked defects in liver morphology. Additionally, Nicolucci *et al* ([@b51-etm-0-0-8193]) reported that patients with liver disease exhibit higher BPA levels compared with normal individuals, suggesting an association between BPA-exposure and the health status of the liver. The results of histopathological examination performed in the current study supports those of biochemical experiments. When compared with control livers, BPA treatment induced the severe disruption of the liver\'s architecture, resulting in cellular infiltration, the formation of large cytoplasmic vacuoles and hepatic sinusoids, and an increased number of Kupffer cells. Hepatic lipid accumulation and oxidative stress, followed by liver injury and inflammation, are pathogenic events for non-alcoholic steatohepatitis ([@b52-etm-0-0-8193]).

The results of the present study revealed significant decreases in the activities of CK-MB, LDH and AST in the BPA-treated group. This indicated that damage or inflammation was present in the heart tissue. Ljunggren *et al* ([@b53-etm-0-0-8193]) demonstrated that BPA alters a number of proteins involved in the structural integrity of the myocardial left ventricle. Furthermore, Aboul *et al* ([@b54-etm-0-0-8193]) reported that BPA generated ROS and reduced the level of antioxidants in rat heart tissue, which may lead to cardiovascular diseases. A further study demonstrated that BPA inhibited the ventricular function of the heart by elevating ROS in myositis, inducing damage ([@b55-etm-0-0-8193]). In addition to inducing oxidative stress, BPA increases VLDL-C and LDL-C, and decreases HDL-C, which are considered to be atherogenic indicators. The estrogen-like effect of BPA has a significant effect on cholesterol, which may be the reason for the development of myocardial infarction and other complications such as arteriosclerotic vascular diseases ([@b56-etm-0-0-8193]). The histopathological examination of rat heart tissue performed in the current study revealed that BPA caused the severe disorganization and degeneration of myocardial fibers, cytoplasmic vacuolization in cardiac muscle and hemorrhages between myofibrils, confirming the presence of damage or inflammation. BPA treatment also induced sclerotic changes in the walls of the dorsal aorta and atrophy of elastic fibers. This was demonstrated by various changes in the tunica intima and media, including fragmentation, disintegration, vacuolation and a marked increase in thickness. In addition, quantitative analysis of the aortic atherosclerotic composition of the BPA-treated group demonstrated a significant increase in its mean wall thickness, indicating atherosclerotic changes.

The results of the current study indicated that sesame lignans attenuated BPA-induced oxidative stress by decreasing MDA, increasing the specific activities of GPx, GR and SOD, and increasing the level of GSH in the livers of S- and BS-group rats. The present study also revealed that sesame lignans supplementation attenuated measured parameters to a level similar to that of the control. This may be due to its free radical scavenging properties. These results are consistent with those of Yashaswini *et al* ([@b22-etm-0-0-8193]). The study revealed that sesame lignans increased the activities of GPx and GR, and decreased MDA levels in LPS-treated rats. Furthermore, Ma *et al* ([@b57-etm-0-0-8193]) reported that sesamin decreased ROS and MDA production in the liver extract of CCL~4~-treated mice. The augmented SOD activity induced by sesame lignans enhances the ability of hepatic cells to decompose superoxide anions produced by BPA into H~2~O~2~, preventing further generation of free radicals. H~2~O~2~ is subsequently broken down by GPx, which uses GSH as a reducing agent. Therefore, increasing GPx activity and GSH levels via sesame lignans should protect liver tissue against oxidative damage ([@b58-etm-0-0-8193]).

In the present study, BPA-induced dyslipidemia and hepatic lipid accumulation were partially or completely attenuated by the co-administration of sesame lignans. Suwimol *et al* ([@b59-etm-0-0-8193]) confirmed the results of the current study by reporting that sesame seed powder reduces hepatic total lipid, plasma cholesterol and LDL-C levels in rats. Sesame lignans decreases cholesterol levels by inhibiting its intestinal absorption, increasing its fecal and biliary excretion, and downregulating hepatic 3-hydroxy-3-methyl gluteryl coenzyme A reductase activity ([@b60-etm-0-0-8193]). The hypotriglyceridemic effect of sesame lignans may be due to the inhibition of lipogenesis, the promotion of fatty acid oxidation and ketogenesis at the expense of its esterification into TG ([@b61-etm-0-0-8193]). Additionally, sesamin increases fat burning and decreases fat storage by activating peroxisome proliferator-activator receptor alpha (PPARα), which induces the expression of β-oxidation enzymes and represses lipogenic enzymes ([@b62-etm-0-0-8193]). Furthermore, PPARα activation increases the level of uncoupling proteins, resulting in the expenditure of more calories and fat loss ([@b63-etm-0-0-8193]). In addition, sesamin has been associated with a reduction of LDL-C and the elevation of HDL-C levels ([@b64-etm-0-0-8193]). The reduction of leptin is another possible mechanism for the sesame lignans-induced inhibition of hepatic lipid accumulation ([@b65-etm-0-0-8193]).

The present study revealed that sesame lignans administration exhibits potent hepatoprotective effects against BPA-induced hepatic damage in rats. It improved the secretory function and structural integrity of liver cells by reducing the activities of serum ALT and AST, and reducing the total bilirubin level, producing results that were lower than the control and BPA-treated groups. These results are consistent with those emphasized by Ma *et al* ([@b57-etm-0-0-8193]) who demonstrated that sesamin effectively reduced serum ALT and AST, and alleviated hepatic histological changes. The hepatoprotective effects exerted by sesame lignans may be due to their anti-inflammatory effects, as sesamin has been reported to inhibit arachidonic acid synthesis and reduce the production of pro-inflammatory cytokines ([@b66-etm-0-0-8193]). Furthermore, sesame lignans possess general anti-inflammatory effects as indicated by their ability to reduce C-reactive protein levels ([@b67-etm-0-0-8193]). The antioxidative effect of sesame lignans and their lipid peroxidation lowering effect contributes to their hepatoprotective effect ([@b17-etm-0-0-8193]). The hepatoprotective effects exerted by sesame lignans were confirmed following histopathological examination, which revealed that sesame lignans attenuated BPA-induced hepatic alterations. The attenuation of hepatic lipid accumulation (steatosis) and peroxidation by sesame lignans may therefore prevent or decrease the pathogenic events of BPA-induced steatohepatitis.

Sesame lignans protected against myocardial tissue damage by lowering the activity of serum AST, LDH and CK-MB when compared with the control. The protective effect of sesame lignans against myocardial injury may be attributed to the enhancement of certain endogenous antioxidants, including GSH, SOD and GPx ([@b68-etm-0-0-8193]). Antioxidants have been revealed to attenuate the progression of cardiovascular diseases in clinical trials ([@b69-etm-0-0-8193]). Furthermore, sesame lignans decreases the risk of cardiovascular diseases by lowering total cholesterol and VLDL-C levels, and elevating HDL-C ([@b70-etm-0-0-8193]). The histopathological examinations performed in the current study demonstrated that sesame lignans treatment decreased the degeneration and vacuolization of myocardial fibers that were induced by BPA. These results are in line with those by Li *et al* ([@b71-etm-0-0-8193]) who demonstrated that sesamin reversed the abnormal changes of the heart and cardiac hypertrophy, and improved myocardial fibrosis. In addition, the morphometric analysis of the dorsal aorta performed in the current study revealed that the histological alterations induced by BPA were markedly reduced by the co-administration of sesame lignans. This was confirmed by the significant reduction of its mean wall thickness, which may further confirm the protective effect of sesame lignans against atherosclerotic plaque deposition in the dorsal aorta. Sesame lignans may be helpful to improve endothelial function and prevent the developments of cardiovascular diseases. The present study had some limitations. The effect of BPA exposure on the degree of liver tissue collagen deposition and on serum levels of troponin I and T should be investigated in future study to confirm its fibrogenic and heart dysfunction effects, respectively. Furthermore, N-acetyl cysteine or vitamin C should be used as a positive control in future studies and the NF-kB signaling pathway should be tested to confirm the protective and antioxidant effects of sesame lignans on hepatic and cardiac tissues.

The results of the current study indicated that sesame lignans attenuated hepatic oxidative stress and protected liver tissue against BPA-induced oxidative damage. Furthermore, BPA-induced increases in serum and liver TC and TG were attenuated by the oral administration of sesame lignans. In addition, sesame lignans restored the liver and heart integrity, as indicated by its ability to attenuate function tests. These results were confirmed by the histopathological examinations. The oral administration of sesame lignans ameliorated BPA-induced histopathological changes in heart and hepatic tissues.
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![Total cholesterol and triglyceride levels in the liver tissue of male rats in each group. Data are presented as mean ± standard error. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the BPA-treated group. C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA and sesame lignans-treated group; BPA, bisphenol A.](etm-19-01-0033-g00){#f1-etm-0-0-8193}

![Serum CK-MB enzyme activity in the different study groups. Data are presented as mean ± standard error. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the BPA-treated group. C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA and sesame lignans-treated group; CK-MB, creatine kinase MB; BPA, bisphenol A.](etm-19-01-0033-g01){#f2-etm-0-0-8193}

![Serum LDH enzyme activity in the different study groups. Data are presented as mean ± standard error. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. the BPA-treated group. C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA plus sesame lignans-treated group; LDH, lactate dehydrogenase; BPA, bisphenol A.](etm-19-01-0033-g02){#f3-etm-0-0-8193}

![Photomicrographs of liver sections. The (A) control and (Ca and Cb) sesame lignans-treated group exhibited normal hepatocyte architecture and central vein with normal blood sinusoids and hepatocytes. (Ba and Bb) Liver sections from the BPA-treated group exhibited distention and hemorrhage in the central and portal vein (red dotted arrow and double headed red arrow, respectively). L, loss of the normal architecture, degenerated hepatocytes with pyknotic nuclei (black circle), vacuolated hepatocytes (black arrows), dilation of blood sinusoids and an increased number of kupffer cells (orange arrows) were also identified. BPA-induced histological changes were markedly reduced in the (D) BPA and sesame lignans-treated group, with moderate improvement in the hepatic cells (H&E staining; magnification, ×400). C.V, central vein; S, sinusoids; H, hepatocytes; BPA, bisphenol A; L, lymphocyte aggregation; b.d, bile duct.](etm-19-01-0033-g03){#f4-etm-0-0-8193}

![Light micrographs of heart tissue. The (A) control and sesame lignans-treated rats (C) exhibited normal myocardial fiber architecture, with branching muscle fibers and centrally located oval nuclei. (Ba and Bb) Sections of heart tissue treated with BPA exhibited a loss of normal architecture, widespread fragmentation and muscle fiber degeneration. Inflammatory and mast cells (black circle) were present in the connective tissue, along with a congested blood vessel (dotted arrow), vacuoles (black arrow) and branches of thickened coronary vessels. (D) Histological alterations induced after BPA-treatment were markedly reduced when treated with BPA and sesame lignans (H&E staining; magnification, ×400). BPA, bisphenol A; c.a. coronary artery.](etm-19-01-0033-g04){#f5-etm-0-0-8193}

![Light micrographs of the dorsal aorta. The (Aa and Ab) control and (Ca and Cb) sesame lignans-treated group exhibited normal tunica intima with a single irregular layer of endothelial cells (black arrow). The tunica media, comprising elastic fibers and the tunica adventitia also appeared normal. (B~a~ and B~b~) The BPA-treated group exhibited sclerotic changes in the walls and atrophy of elastic fibers (green arrows), loss of the tunica intima endothelial cells, disorganized and vacuolation of the tunica media (blue-arrow), increased adventitial thickness and decreased lumen size of the aorta (double-headed arrows) compared with the control group. (Da and Db) Histological changes induced after BPA-treatment were markedly reduced in the BPA and sesame lignans-treated group (H&E staining; Aa, Ba, Ca and Da magnification, ×200; Ab, Bb, Cb, and Db magnification, ×400). I, tunica intima; M, tunica media; a, tunica adventitia.](etm-19-01-0033-g05){#f6-etm-0-0-8193}

###### 

Effect of orally administered BPA and/or sesame lignans on the liver function of male rats.

                            Animal treatment                                                                                                                                                                      
  ------------------------- ------------------ ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Activity of AST (U/l)     24.60±1.42         39.43±1.05^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"}^   17.73±0.69^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"},[b](#tfn3-etm-0-0-8193){ref-type="table-fn"}^   23.09±2.77^[b](#tfn3-etm-0-0-8193){ref-type="table-fn"}^
  Activity of ALT (U/l)     14.66±0.78         34.92±0.96^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"}^   5.56±0.78^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"},[b](#tfn3-etm-0-0-8193){ref-type="table-fn"}^    10.13±1.12^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"},[b](#tfn3-etm-0-0-8193){ref-type="table-fn"}^
  Total bilirubin (mg/dl)   0.35±0.03          0.79±0.05^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"}^    0.09±0.01^[a](#tfn2-etm-0-0-8193){ref-type="table-fn"},[b](#tfn3-etm-0-0-8193){ref-type="table-fn"}^    0.27±0.02^[b](#tfn3-etm-0-0-8193){ref-type="table-fn"}^

Data are presented as mean ± SE.

P\<0.05 vs. the control group

P\<0.05 vs. the BPA-treated group. BPA, bisphenol A; AST, aspartate aminotransferase; ALT, alanine aminotransferase; C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA and sesame lignans-treated group.

###### 

Effect of BPA and/or sesame lignans on the lipid profile of male rats.

                 Animal treatment                                                                                                                                                                         
  -------------- ------------------ ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Cholesterol    186.70±1.58        271.38±1.00^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"}^    153.33±1.13^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^   212.91±8.19^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^
  LDL-C          102.68±3.02        159.04±5.71^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"}^    72.05±2.96^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^    95.31±2.46^[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^
  HDL-C          39.72±1.06         12.22±1.87^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"}^     46.41±1.79^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^    34.79±1.12^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^
  VLDL-C         32.68±2.20         73.02±3.60^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"}^     15.40±1.24^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^    29.82±1.57^[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^
  Triglyceride   163.43±11.01       365.14±18.03^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"}^   73.14±6.13^[a](#tfn5-etm-0-0-8193){ref-type="table-fn"},[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^    150.28±7.52^[b](#tfn6-etm-0-0-8193){ref-type="table-fn"}^

Data are presented as mean ± SE.

P\<0.05 vs. the control group

P\<0.05 vs. the BPA-treated group. BPA, bisphenol A; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA and sesame lignans-treated group.

###### 

Effect of orally administered BPA and/or sesame lignans on the liver oxidant and antioxidant status of rats.

                          Animal treatment                                                                                                                                                                          
  ----------------------- ------------------ ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  MDA (nmol/gm tissue)    438.80±11.73       626.80±35.62^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"}^   223.80±16.03^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^   325.20±8.96^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^
  GSH (nmol/mg protein)   19.04±0.96         8.76±1.12^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"}^      36.57±2.66^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^     23.35±0.43^[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^
  GR (mu/mg protein)      15.01±0.93         8.72±0.39^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"}^      17.75±0.92^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^     12.44±0.76^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^
  GPx (mu/mg protein)     644.75±20.19       403.72±11.35^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"}^   838.40±27.72^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^   658.40±13.41^[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^
  SOD (U/mg protein)      4.44±0.19          2.28±0.27^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"}^      5.31±0.32^[a](#tfn8-etm-0-0-8193){ref-type="table-fn"},[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^      3.68±0.35^[b](#tfn9-etm-0-0-8193){ref-type="table-fn"}^

Data are presented as mean ± SE.

P\<0.05 vs. the control group

P\<0.05 vs. the BPA-treated group. BPA, bisphenol A; MDA, malondialdehyde; GSH, reduced glutathione; GR, glutathione reductase; GPx, glutathione peroxidase; SOD, superoxide dismutase; C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA and sesame lignans-treated group.

###### 

Effect of BPA and/or sesame lignans on the wall thickness of male rat dorsal aortas.

                        Animal treatment                                                                                                                             
  --------------------- ------------------ ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------
  Wall thickness (µm)   165.85±0.34        293.65±0.26^[a](#tfn11-etm-0-0-8193){ref-type="table-fn"}^   161.50±0.57^[b](#tfn12-etm-0-0-8193){ref-type="table-fn"}^   171.95±0.68^[b](#tfn12-etm-0-0-8193){ref-type="table-fn"}^

Data are presented as mean ± SE.

P\<0.05 vs. the control group

P\<0.05 vs. the BPA treated-group. BPA, bisphenol A; C-group, control group; B-group, BPA-treated group; S-group, sesame lignans-treated group; BS-group, BPA and sesame lignans-treated group.
